- Home
- HYPR vs MIST Comparison
HYPR vs MIST Comparison
Compare HYPR & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- MIST
- Stock Information
- Founded
- HYPR 2014
- MIST 2003
- Country
- HYPR United States
- MIST Canada
- Employees
- HYPR N/A
- MIST N/A
- Industry
- HYPR Medical Specialities
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- MIST Health Care
- Exchange
- HYPR Nasdaq
- MIST Nasdaq
- Market Cap
- HYPR 54.6M
- MIST 53.9M
- IPO Year
- HYPR N/A
- MIST N/A
- Fundamental
- Price
- HYPR $0.61
- MIST $1.17
- Analyst Decision
- HYPR Strong Buy
- MIST Strong Buy
- Analyst Count
- HYPR 3
- MIST 2
- Target Price
- HYPR $1.13
- MIST $9.50
- AVG Volume (30 Days)
- HYPR 269.5K
- MIST 1.6M
- Earning Date
- HYPR 05-13-2025
- MIST 05-14-2025
- Dividend Yield
- HYPR N/A
- MIST N/A
- EPS Growth
- HYPR N/A
- MIST N/A
- EPS
- HYPR N/A
- MIST N/A
- Revenue
- HYPR $11,732,000.00
- MIST N/A
- Revenue This Year
- HYPR $24.00
- MIST N/A
- Revenue Next Year
- HYPR $28.70
- MIST N/A
- P/E Ratio
- HYPR N/A
- MIST N/A
- Revenue Growth
- HYPR 0.34
- MIST N/A
- 52 Week Low
- HYPR $0.58
- MIST $0.63
- 52 Week High
- HYPR $1.90
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- HYPR 35.57
- MIST 47.29
- Support Level
- HYPR $0.66
- MIST $1.10
- Resistance Level
- HYPR $0.80
- MIST $1.23
- Average True Range (ATR)
- HYPR 0.06
- MIST 0.11
- MACD
- HYPR -0.00
- MIST 0.01
- Stochastic Oscillator
- HYPR 8.94
- MIST 20.55
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).